A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma in the United Kingdom (UK)
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ipsen
- 30 Jan 2019 Status changed from not yet recruiting to recruiting.
- 20 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Dec 2018.
- 12 Oct 2018 New trial record